[ad_1]
The National Institute for Food and Drug Monitoring (INVIMA) announced by a press release the withdrawal of the local market from any type of drug that contains as raw material Valsartan supplier Zhejiang Huahai Pharmaceuticals currently used by patients with hypertension.
"The substance Ndma was clbadified as probably carcinogenic by the International Agency for Research on Cancer (IARC) and its presence is highlighted in tobacco smoke, some processed foods and some toiletries, "says the document.
For this reason, the information indicates that the Invima and the holders of medical records of the laboratories American Generics, Genfar, Humax Pharmaceutical, Laboratoire Franco Colombiano Lafrancol, MK Laboratories, Lafrancol Internacional, Procaps, Sanofi-Aventis of Colombia, Tecnochimie Winthrop Pharmaceuticals of Colombia determined the voluntary withdrawal of their drugs containing valsartan from the market.
However, Invima indicated that the People who are currently using this type of medication should not suspend it without first consulting their doctor.
[ad_2]
Source link
